CGOC Name Change to PBIC; CMX's Cannabinoids and Psychotherapeutics Practice Group (February 1, 2021)

01 Feb 2021 | News

CGOC Name Change to PBIC; CMX’s Cannabinoids and Psychotherapeutics Practice Group (February 1, 2021)

CGOC Name Change to PBIC; CMX's Cannabinoids and Psychotherapeutics Practice Group (February 1, 2021)

01 Feb 2021 | News

CGOC Name Change to PBIC; CMX's Cannabinoids and Psychotherapeutics Practice Group (February 1, 2021)

February 1, 2021

To our Clients and Friends:

Paul Crath, Chief Executive Officer of Cannabis Growth Opportunity Corporation ("CGOC), a co-founder of Crath Miller & Xistris LLP, and Head of our Capital Markets practice group, announced recently that CGOC, a cannabis-focused investment corporation has changed its name to "Plant-Based Investment Corp." (“PBIC”) effective January 15, 2021.  The Company's trades on the Canadian Securities Exchange (the "CSE") and its stock symbol is "PBIC".

Mr. Crath stated, "In connection with a repositioning of CGOC's public and private investment platform and to reflect certain market opportunities identified by management, the board of directors determined to proceed with a name change to "Plant-Based Investment Corp." to better reflect management's focus on investments that relate to the broader cannabis plant family, including hemp plants, cannabinoids, including CBD, CBG and CBN, along with other terpenes and flavonoids found in cannabis and other plants. Furthermore, there are new opportunities with combinatorial products and their related intellectual property resulting from combining cannabis plant compounds with other functional plant- and fungi-based ingredients."

To better meet the current needs of its clients,  CMXLaw has renamed its practice group to “Cannabinoids and Psychotherapeutics” to expand its focus to include the emerging psychotherapeutics, including psilocybins, as well as alternative fungi and plant-based products and technologies.  This practice group will continue to advise clients on the evolving array of Federal and State regulatory regimes, local and state law licensing, regulatory compliance and product labelling issues.  Our clients involved in Cannabinoids and Psychotherapeutics also remain active with CMXLaw’s Finance and Banking, Capital Markets, Securities and Tax practice groups.

See PBIC Press Release (1-19-2021)

Paul can be reached at and at +1 (347) 835-9032

CMXLaw has offices in New York and California.


Crath Miller & Xistris LLP

For further information, please contact us at

The materials contained in this message and website pages, whitepapers, advisories and other items directly linked to it have been prepared for general informational purposes only and should not be construed or relied upon as legal advice or a legal opinion on any specific facts and circumstances. The publication and dissemination, including on-line, of these materials and receipt, review, response to or other use of them does not create or constitute an attorney-client relationship.

To ensure compliance with requirements imposed by the Internal Revenue Service, we inform you that any tax advice contained in this communication (including any attachments) was not intended or written to be used, and cannot be used, for the purpose of (i) avoiding tax-related penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party any tax-related matter(s) addressed herein.

These materials may contain attorney advertising. Prior results do not guarantee a similar outcome.

Copyright © Crath Miller & Xistris LLP 2021. All Rights Reserved.